South Dakota Investment Council bought a new position in shares of PAREXEL International Corporation (NASDAQ:PRXL) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,600 shares of the medical research company’s stock, valued at approximately $1,095,000.

Several other institutional investors have also modified their holdings of PRXL. Capstone Asset Management Co. raised its holdings in shares of PAREXEL International Corporation by 3.8% during the first quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock worth $278,000 after purchasing an additional 160 shares during the last quarter. Glen Harbor Capital Management LLC grew its position in PAREXEL International Corporation by 7.1% during the first quarter. Glen Harbor Capital Management LLC now owns 2,520 shares of the medical research company’s stock valued at $159,000 after buying an additional 168 shares during the period. Oregon Public Employees Retirement Fund grew its position in PAREXEL International Corporation by 1.1% during the first quarter. Oregon Public Employees Retirement Fund now owns 18,537 shares of the medical research company’s stock valued at $1,170,000 after buying an additional 200 shares during the period. First Trust Advisors LP grew its position in PAREXEL International Corporation by 216.7% during the first quarter. First Trust Advisors LP now owns 29,536 shares of the medical research company’s stock valued at $1,864,000 after buying an additional 20,210 shares during the period. Finally, Elkfork Partners LLC grew its position in PAREXEL International Corporation by 7.1% during the first quarter. Elkfork Partners LLC now owns 3,060 shares of the medical research company’s stock valued at $193,000 after buying an additional 204 shares during the period. 87.48% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/14/12600-shares-in-parexel-international-corporation-prxl-acquired-by-south-dakota-investment-council.html.

Several research firms recently commented on PRXL. Zacks Investment Research upgraded shares of PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research report on Tuesday, August 8th. Barclays PLC lowered shares of PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a research report on Tuesday, June 20th. Jefferies Group LLC restated a “hold” rating and set a $88.10 price target on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Raymond James Financial, Inc. upgraded shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Finally, Goldman Sachs Group, Inc. (The) upgraded shares of PAREXEL International Corporation from a “sell” rating to a “neutral” rating and raised their price target for the company from $63.00 to $77.00 in a research report on Tuesday, May 23rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $75.92.

Shares of PAREXEL International Corporation (PRXL) opened at 87.93 on Thursday. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of 42.68 and a beta of 0.79. The stock has a 50 day moving average of $87.67 and a 200 day moving average of $77.32. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $87.98.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.08. The company had revenue of $557.20 million during the quarter, compared to the consensus estimate of $537.59 million. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. During the same quarter in the prior year, the firm earned $0.94 EPS. On average, equities research analysts expect that PAREXEL International Corporation will post $3.95 EPS for the current fiscal year.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.